Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer

Daniel J. Schaid, Shannon K. McDonnell, Liesel M. FitzGerald, Lissa DeRycke, Zachary Fogarty, Graham G. Giles, Robert J. MacInnis, Melissa C. Southey, Tu Nguyen-Dumont, Geraldine Cancel-Tassin, Oliver Cussenot, Alice S. Whittemore, Weiva Sieh, Nilah Monnier Ioannidis, Chih Lin Hsieh, Janet L. Stanford, Johanna Schleutker, Cheryl D. Cropp, John Carpten, Josef HoegelRosalind Eeles, Zsofia Kote-Jarai, Michael J. Ackerman, Christopher J. Klein, Diptasri Mandal, Kathleen A. Cooney, Joan E. Bailey-Wilson, Brian Helfand, William J. Catalona, Fredrick Wiklund, Shaun Riska, Saurabh Bahetti, Melissa C. Larson, Lisa Cannon Albright, Craig Teerlink, Jianfeng Xu, William Isaacs, Elaine A. Ostrander, Stephen N. Thibodeau

Research output: Contribution to journalArticleResearchpeer-review

26 Citations (Scopus)


Background: Family history of prostate cancer (PCa) is a well-known risk factor, and both common and rare genetic variants are associated with the disease. Objective: To detect new genetic variants associated with PCa, capitalizing on the role of family history and more aggressive PCa. Design, setting, and participants: A two-stage design was used. In stage one, whole-exome sequencing was used to identify potential risk alleles among affected men with a strong family history of disease or with more aggressive disease (491 cases and 429 controls). Aggressive disease was based on a sum of scores for Gleason score, node status, metastasis, tumor stage, prostate-specific antigen at diagnosis, systemic recurrence, and time to PCa death. Genes identified in stage one were screened in stage two using a custom-capture design in an independent set of 2917 cases and 1899 controls. Outcome measurements and statistical analysis: Frequencies of genetic variants (singly or jointly in a gene) were compared between cases and controls. Results and limitations: Eleven genes previously reported to be associated with PCa were detected (ATM, BRCA2, HOXB13, FAM111A, EMSY, HNF1B, KLK3, MSMB, PCAT1, PRSS3, and TERT), as well as an additional 10 novel genes (PABPC1, QK1, FAM114A1, MUC6, MYCBP2, RAPGEF4, RNASEH2B, ULK4, XPO7, and THAP3). Of these 10 novel genes, all but PABPC1 and ULK4 were primarily associated with the risk of aggressive PCa. Conclusions: Our approach demonstrates the advantage of gene sequencing in the search for genetic variants associated with PCa and the benefits of sampling patients with a strong family history of disease or an aggressive form of disease. Patient summary: Multiple genes are associated with prostate cancer (PCa) among men with a strong family history of this disease or among men with an aggressive form of PCa.

Original languageEnglish
Pages (from-to)353-361
Number of pages9
JournalEuropean Urology
Issue number3
Publication statusPublished - Mar 2021


  • Custom-capture sequencing
  • Familial prostate cancer
  • Genetic risk variants
  • Whole-exome sequencing

Cite this